Literature DB >> 28562196

Antitumor and Anti-Hepatitis C Viral Response After Administration of the Anti-Programmed Death 1 Antibody Pembrolizumab.

Sekwon Jang1, Suraj Venna1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28562196     DOI: 10.1200/JOP.2016.019224

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN: 1554-7477            Impact factor:   3.840


× No keyword cloud information.
  4 in total

Review 1.  Immunotherapy use outside clinical trial populations: never say never?

Authors:  K Rzeniewicz; J Larkin; A M Menzies; S Turajlic
Journal:  Ann Oncol       Date:  2021-03-24       Impact factor: 51.769

2.  The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC).

Authors:  Ezra E W Cohen; R Bryan Bell; Carlo B Bifulco; Barbara Burtness; Maura L Gillison; Kevin J Harrington; Quynh-Thu Le; Nancy Y Lee; Rom Leidner; Rebecca L Lewis; Lisa Licitra; Hisham Mehanna; Loren K Mell; Adam Raben; Andrew G Sikora; Ravindra Uppaluri; Fernanda Whitworth; Dan P Zandberg; Robert L Ferris
Journal:  J Immunother Cancer       Date:  2019-07-15       Impact factor: 13.751

3.  Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer: A systematic review.

Authors:  Dan Pu; Liyuan Yin; Yuwen Zhou; Wen Li; Lin Huang; Liang Cai; Qinghua Zhou
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.889

Review 4.  Checkpoint inhibitor use in two heart transplant patients with metastatic melanoma and review of high-risk populations.

Authors:  Michael J Grant; Nicholas DeVito; April K S Salama
Journal:  Melanoma Manag       Date:  2018-10-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.